Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

People suffering from the early onset of Alzheimer's disease are being given access to a revolutionary drug that's being hailed as a potential cure. The drug, Xanamem, works by blocking the ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli ...